国色A片V一区二区三区下,把女人弄爽特黄a大片,扒开粉嫩小泬直接进视频,久久久久 亚洲 无码 AV 专区

您好，歡迎光臨上海雅吉生物商城！
工作時(shí)間：9:00-18:00
全國服務(wù)熱線：021-34661276

APC anti-mouse CD274 (B7-H1, PD-L1) Antibody

訂購數(shù)量：
規(guī)格
價(jià)格庫存
訂購熱線：021-34661276
我要詢價(jià)
  • 商品詳情
  • 售后服務(wù)
  • 相關(guān)文獻(xiàn)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunofluorescence4, blocking6,7,8,9, and immunohistochemistry of acetone-fixed frozen sections4, 11. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 124303). For highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 124318) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin <0.01 EU/?g).

Application References

(PubMed link indicates BioLegend citation)
  1. Maier H, et al. 2007. J. Immunol. 178:2714.
  2. Meng Q, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:4444. PubMed
  3. Scarlett UK, et al. 2012. J Exp Med. 209:495. PubMed
  4. Grabie N, et al. 2007. Circulation 116:2062. (IF, IHC)
  5. Paterson AM, et al. 2011. J. Immunol. 187:1097.
  6. Channappanavar R, et al. 2012. PLoS One 7:e39757. (Block)
  7. Schreiber HA, et al. 2010. PLoS One 5:e11453. (Block) PubMed
  8. Muthumani K, et al. 2011. J. Immunol. 187:2932. (Block) PubMed
  9. Cripps JG, et al. 2010. Hepatology 52:1350. (Block) PubMed
  10. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  11. Riella LV, et al. 2011. Am. J. Transplant 11:832-40. (IHC)
  12. Lei GS, et al. 2015. Infect Immun. 83:572. PubMed
Product Citations
  1. Ngiow S, et al. 2016. Cancer Res . 76: 6266 - 6277. PubMed
  2. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
  3. Chan LC, et al. 2019. J Clin Invest. 129:3324. PubMed
  4. Yonemitsu K, et al. 2022. Sci Rep. 12:12007. PubMed
  5. Tatsuguchi T, et al. 2022. Int Immunol. 34:277. PubMed
  6. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  7. Pierini S, et al. 2021. J Immunother Cancer. 9:. PubMed
  8. Park S, et al. 2021. Front Immunol. 11:620166. PubMed
  9. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  10. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  11. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  12. Kim TJ, et al. 2019. Nat Commun. 10:3258. PubMed
  13. Lin R, et al. 2020. Sci Rep. 10:14397. PubMed
  14. Zhang C, et al. 2022. J Extracell Vesicles. 11:e12209. PubMed
  15. Ren J, et al. 2021. Theranostics. 11:304. PubMed
  16. Chen L, et al. 2020. Cancer Immunol Res. 0.457638889. PubMed
  17. Fu Y, et al. 2020. Sci Rep. 10:9027. PubMed
  18. Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed
  19. Bommireddy R, et al. 2020. Vaccines (Basel). 8:. PubMed
  20. Findlay EG, et al. 2019. Oncoimmunology. 8:1608106. PubMed
  21. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  22. Zhang C, et al. 2020. Cell Metabolism. 31(1):148-161.e5.. PubMed
  23. Zhou KX, et al. 2021. J Immunol Res. 2021:6694392. PubMed
  24. Tu J, et al. 2022. Theranostics. 12:747. PubMed
  25. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  26. Pein M, et al. 2020. Nat Commun. 11:1494. PubMed
  27. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  28. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
  29. Guo L, et al. 2021. Front Immunol. 12:785457. PubMed
  30. Lovisa S, et al. 2020. Sci Signal. 13:00. PubMed
  31. Zhou L, et al. 2020. Clin Cancer Res. 26:290. PubMed
  32. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  33. Kennedy EM, et al. 2022. Nat Commun. 13:5907. PubMed
  34. Pradhan K, et al. 2021. Front Immunol. 12:778830. PubMed
  35. Poon E, et al. 2017. J Immunother Cancer. 10.1186/s40425-017-0268-8. PubMed
  36. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  37. Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed
  38. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
  39. Koikawa K, et al. 2021. Cell. 184(18):4753-4771.e27. PubMed
  40. Vardhana SA, et al. 2020. Nat Immunol. 1.584722222. PubMed
  41. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  42. Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed
  43. Almishri W, et al. 2015. J Hepatol. 63: 943-951. PubMed
  44. Fukumoto T, et al. 2019. Cancer Res. 79:5482. PubMed
  45. Yuan M, et al. 2022. Oxid Med Cell Longev. 2022:5479491. PubMed
  46. Shen ZY, et al. 2021. Front Immunol. 12:589200. PubMed
  47. Williams JB, et al. 2020. Nat Commun. 0.876388889. PubMed
  48. Franklin DA, et al. 2020. JCI Insight. 5:. PubMed
  49. Baldwin LA, et al. 2022. Nat Commun. 13:6539. PubMed
  50. Barbet G, et al. 2018. Immunity. 48:584. PubMed
  51. Iwata TN, et al. 2018. Mol Cancer Ther. 17:1494. PubMed
  52. Yi M, et al. 2022. J Hematol Oncol. 15:142. PubMed
  53. Li Q, et al. 2022. Front Oncol. 12:841977. PubMed
  54. Lindhorst A, et al. 2021. Cell Death Dis. 12:579. PubMed
  55. Vogel A, et al. 2022. Cell Rep. 38:110420. PubMed
  56. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  57. Kataru RP, et al. 2019. Cancer Immunol Res. 7:1345. PubMed
  58. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  59. Zheng C, et al. 2022. Acta Pharm Sin B. 12:3726. PubMed
  60. Shen H, et al. 2022. Nat Commun. 13:5013. PubMed
  61. Lin J, et al. 2021. Cancer Immunol Res. 9:1413. PubMed
  62. Liu YS, et al. 2021. Cancers (Basel). 13:. PubMed
  63. Luna-Yolba R, et al. 2021. Cancers (Basel). 13: . PubMed
  64. Freed-Pastor WA, et al. 2021. Cancer Cell. :. PubMed
  65. Wang C, et al. 2018. Sci Transl Med. 10. PubMed
  66. Shaashua L, et al. 2022. Nat Commun. 13:6513. PubMed
  67. RL M, et al. 2015. Proc Natl Acad Sci U S A. 112:6506-6514. PubMed
  68. Lerbs T, et al. 2020. JCI Insight. 5:00. PubMed
  69. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  70. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  71. Luo N, et al. 2018. Nat Commun. 0.547222222. PubMed
RRID
AB_10612935 (BioLegend Cat. No. 124311) AB_10612741 (BioLegend Cat. No. 124312)

Antigen Details

Structure
40 kD type I transmembrane protein member of B7 family within the immunoglobulin receptor superfamily
Distribution

T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes

Ligand/Receptor
PD-1 (PDCD1)
Cell Type
B cells, Dendritic cells, Endothelial cells, Monocytes, NK cells, T cells
Biology Area
Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family
Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.
2. Dong H, et al. 1999. Nat. Med. 5:1365.
3. Freeman G, et al. 2000. J. Exp. Med. 192:1027.

Gene ID
60533 View all products for this Gene ID
UniProt
View information about CD274 on UniProt.org
我要詢價(jià)
*聯(lián)系方式：
(可以是QQ、MSN、電子郵箱、電話等，您的聯(lián)系方式不會(huì)被公開)
*內(nèi)容：


微信客服
掃一掃立即咨詢


微信客服
掃一掃立即咨詢

銷售電話：

021-34661275

021-34661276

15301693058